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Abstract 
Machine learning provides a broad framework for addressing high-dimensional prediction problems in 
classification and regression. While machine learning is often applied for imaging problems in medical 
physics, there are many efforts to apply these principles to biological data towards questions of radiation 
biology. Here, we provide a review of radiogenomics modeling frameworks and efforts towards 
genomically-guided radiotherapy. We first discuss medical oncology efforts to develop precision 
biomarkers. We next discuss similar efforts to create clinical assays for normal tissue or tumor 
radiosensitivity. We then discuss modeling frameworks for radiosensitivity and the evolution of machine 
learning to create predictive models for radiogenomics. 
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1 Introduction 
In radiotherapy, radiogenomics is the study of the totality of genomic variation that affect the response 
of normal and tumor tissue to radiation.1–3 There is significant interest in incorporating radiogenomics to 
guide personalize radiotherapy treatments.4,5 Machine learning (ML) rose as a merger of computer 
science and statistics that provides a computationally-scalable framework for addressing high-
dimensional classification and regression for prediction problems. ML is widely used in genomics for 
various tasks6–8 and there are similar efforts to apply ML to high-dimensional radiogenomics datasets to 
create predictive models.9 Like many fields in medicine, radiation oncology has taken significant interest 
in applying ML for several aspects of its practice.10–14 Notable cooperative efforts in the United States 
include the American Association of Physicists in Medicine (AAPM) Practical Big Data Workshop (annually 
since 2017)15 and a recently concluded National Cancer Institute (NCI) workshop on Artificial Intelligence 
in Radiation Oncology in April 2019. 
In this review article, we begin with a background of genomically-guided therapies in medical oncology. 
We then contrast this with radiogenomics, beginning with efforts to predict normal tissue radiosensitivity 
before moving to the prediction of tumor radiosensitivity. Next, we discuss various frameworks for 
modeling radiosensitivity and how radiogenomics can augment these models. We then discuss the role 
and application of ML methods for specific radiogenomics applications to predict normal tissue and/or 
tumor radiosensitivity.  
2 Precision oncology 
While its precise definition is evolving, “precision oncology” generally is described as using genetic 
information to find targets for systemic agents.16 Early examples of precision oncology focused on single 
mutations, such as imatinib to target BCR-ABL translocation in chronic myelogenous leukemia or 
trastuzumab to target HER2-neu oncogene amplification in breast cancer. In the last half decade, targeted 
therapies for specific tyrosine kinase mutations in lung cancer and melanoma have become standard of 
care.  
2.1 NCI precision medicine trials 
In March 2017, the US Food and Drug Administration (FDA) granted a tissue-agnostic “blanket approval” 
to the PD-1 inhibitor pembrolizumab for any metastatic or unresectable solid tumor with high 
microsatellite instability or deficiency in mismatch repair.17 The rationale was the improved response rate 
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and progression-free survival seen in colorectal tumors with genomic instability due to higher number of 
tumor neoantigens and lymphocytic infiltrates.18 This approval marked the first time the FDA approved a 
drug for specific mutations independent of tissue type. 
We can expect this pattern will only increase as the NCI is funding several “precision medicine” trials that 
are weighing mutational burden to guide therapy over the traditional method of being tissue-specific.19 
NCI-MATCH (for specific gene mutations) and NCI-MPACT (for mutations in specific pathways) are taking 
this tissue-agnostic, mutation-specific approach to targeted therapy.20 The NCI-COG Pediatric MATCH is a 
similar to NCI-MATCH except patients will also have germline sequencing to determine whether the tumor 
genetic variants were inherited or not. 
2.2 Biomarkers for decision making 
In oncology, prognostic biomarkers provide treatment-agnostic information about a patient’s outcome 
whereas predictive biomarkers provide information about whether a patient will benefit from a specific 
treatment.21 The key point in the NCI-funded precision oncology trials is that regardless whether a 
biomarker is prognostic or predictive,22 the result should alter the management of a patient. Even though 
prognostic biomarkers do not predict for benefit from a specific therapy, they can still change 
management in the right clinical context. In prostate cancer, serum prostate specific antigen (PSA) and 
pathologic Gleason grade are well-established prognostic biomarkers.23 However, given that favorable 
PSA and Gleason grade are associated with a 99.9% 15-year survival from prostate cancer without upfront 
treatment,24 the standard of care is to recommend against upfront radical treatment in patients in this 
very low risk category to avoid the toxicity of local treatment.25 Similarly in gene panels, breast cancer 
patients who met criteria for adjuvant chemotherapy but had a low Oncotype DX26 Recurrence Score® ≤11 
were prospectively given hormone therapy alone and observed to have 5-year recurrence rate of only 1-
2%.27 Even in the absence of randomized evidence for this low risk category, the standard of care is to 
avoid the toxicity of chemotherapy in this low risk group. 
In general, prognostic models that were not trained on an untreated cohort have limited ability to alter 
management as it can be difficult to distinguish causal effect of treatment vs. favorable biology of a 
treated cohort. For example, Speers et al. created a radiosensitivity signature for breast cancer local 
recurrence by training and validating on two cohorts treated with adjuvant radiation.28 The authors note, 
however, that their signature is unable to differentiate between a radioresistant cancer and a cancer with 
aggressive biology. Similarly, this signature would be unable to differentiate between a radiosensitive 
cancer and a cancer with indolent biology. 
Further confusion occurs when a biomarker appears to have both prognostic and predictive value. While 
temozolomide chemotherapy has shown to significantly increase overall survival in O-6-methylguanine-
DNA methyltransferase (MGMT) gene promoter-methylated glioblastoma, this benefit is significantly 
attenuated (if it exists at all) in non-MGMT promoter-methylated glioblastoma.29,30 However, the 
methylation itself seemed to have prognostic significance independent of temozolomide, with the recent 
NOA-09 trial of only MGMT promoter-methylated patients showing unprecedented survival of 31 months 
in the standard arm.31,32 
While there can be vigorous debate about whether a biomarker is predictive or prognostic,33–36 the focus 
should remain on the potential for a biomarker to alter clinical management. 
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3 Normal tissue radiosensitivity 
Radiation oncology generally aims for 5-10% clinically-significant toxicity to organs at risk in clinical trials. 
As a result, the patients with the most radiosensitive normal tissue ultimately determine the limit for the 
maximum dosage for all patients.4 It is no coincidence that the adjacent organ-at-risk dose tolerance and 
the recommended prescription dose mirror each other for most solid tumors. In contrast, medical 
oncology trialists will often accept in excess of 60% grade 3+ toxicities for advanced or metastatic 
disease.37–39 These studies suggest that patients with more advanced disease are more willing to accept 
higher toxicity for an improved probability of survival, which is in agreement with a focus on better 
prediction of individualized toxicity. 
3.1 Improving treatment planning 
Normal tissue radiotherapy response depends on several factors. Ever since the early days of isoeffect 
curves, we have known that different tissue types have different radiosensitivities. To address this, organ-
specific guidelines were published in the QUANTEC (Quantitative Analysis of Normal Tissue Effects in the 
Clinic) special edition of the Red Journal in 2010.40 However, much progress has been made in the 9 
intervening years. QUANTEC was published during a transition period from 3D conformal radiation to 
intensity-modulated radiation therapy (IMRT), yet QUANTEC dose tolerances have commonly carried over 
for IMRT planning. Given the improved conformality of moderate-high dose region in IMRT, these 
constraints likely represent overly conservative measures for most organ sites. Hypofractionation—both 
moderate and stereotactic-level—was also not addressed but has since become standard of care for 
several of the most commonly treated organ sites. ASTRO guidelines for hypofractionated or stereotactic 
treatment have published within past 2 years for lung,41 prostate,42 and breast cancer.43 Since QUANTEC, 
there have been similar efforts by PENTEC44 (Pediatric Normal Tissue Effects in the Clinic) and the AAPM 
working group HyTEC45 (Hypofractionation Treatment Effects in the Clinic) to determine normal tissue 
effects for pediatric patients and hypofractionated regimens, respectively. 
3.2 Genomic basis for radiosensitivity 
While these advances by QUANTEC, PENTEC and HyTEC hold significant promise, they focus primarily on 
dose constraints and largely omit non-dosimetric clinical factors which can affect organ function following 
radiotherapy, such as diabetes, vasculopathy, hypertension or smoking.46 Efforts from the 1980-1990s 
studying skin toxicity in breast cancer suggested a patient’s toxicity could be tissue-specific,47 temporally-
specific48 (i.e., acute did not necessarily predict for late toxicity) and dominated by a genetic as opposed 
to a dosimetric component.49 These works provided early evidence of genetic predisposition to 
radiosensitivity and suggested that there were not only rare-yet-highly-penetrant radiosensitivity genes 
(i.e. ATM), but also more subtle genetic biomarkers that do not manifest until directly insulted with 
radiotherapy.  
3.2.1 SNP analysis: candidate gene 
With the advent of genome-wide genotyping and next-generation sequencing in the 2000s, cost-effective 
and high-throughput efforts to investigate the genetic component of radiotherapy toxicity became 
possible. Analysis with single nucleotide polymorphisms (SNPs), which are single nucleotide variations 
between individuals, was—and still is—a popular method due to its low cost and ability to capture the 
majority of common (allele frequency ≥ 5%) SNPs across the genome. Most of the early radiogenomics 
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studies used a candidate gene approach where SNPs were pre-selected for their proximity to genes known 
to be involved in cellular radiosensitivity. Early candidate gene studies were often small, underpowered, 
and performed with a poor understanding of important statistical issues, namely, false discovery due to 
uncorrected multiple hypothesis testing.50 Unsurprisingly, validation studies with independent cohorts 
would fail to replicate these associations and suggest publication bias.51,52  
In response, the international Radiogenomics Consortium (RgC; epi.grants.cancer.gov/radiogenomics/) 
was formed in 2009 to expand knowledge of the genetic basis for radiosensitivity differences in patients 
and to develop assays to help predict susceptibility for the development of adverse effects from 
radiotherapy.53,54 The RgC aims to foster international collaborative projects, share biospecimens and 
data, develop guidelines to improve the standardization of radiogenomics research, and provide a forum 
and framework for discussion, development and pursuit of new research directions. In recognition of the 
dearth of new junior investigators in the field, the RgC also supports the development of early career 
investigators and facilitates mentoring relationships across academic institutions. While achieving large 
sample sizes for cohorts with detailed radiation dosimetry, toxicity, and SNP data is an ongoing challenge, 
the RgC has been key in increasing study sizes and, correspondingly, statistical power. Newer candidate 
gene analyses have generally validated findings on independent cohorts. RgC members have found and 
validated SNPs associated with late skin, fibrotic, and overall toxicity after breast cancer radiotherapy 
upstream to inflammatory cytokine TNFA55 (rs1800629, rs2857595) and within base-excision repair gene 
XRCC1 (rs2682585).56 A large meta-analysis validated the association of rs1801516 in DNA double-strand 
break (DSB) repair gene ATM with several acute and late toxicities in breast and prostate cancer, thus 
mimicking a milder phenotype of ataxia-telangiectasia syndrome.57 The Liao group has identified and 
validated SNPs to predict for Grade ≥3 toxicity after lung cancer radiotherapy. These include SNPs in heat 
shock protein HSPB1 associated with pneumonitis58 and esophagitis,59 and rs1800469  in profibrotic 
cytokine TGFB1 associated with esophagitis.60 The role of the rs1800469 SNP remains unclear, and may 
be tissue-specific. RgC members performed an individual-patient meta-analysis of 2782 patients from 11 
cohorts to assess for association of rs1800469 with late fibrosis or late overall toxicity (using a harmonized 
average score) in breast radiotherapy and found no association with multivariable odds ratio 0.98 (95% 
confidence interval 0.85-1.11).61 However, Grossberg et al. report a positive association following breast 
radiotherapy with odds ratio 4.47 (95% confidence interval 1.22-15.99) as assessed  with the Late Effects 
Normal Tissue/Subjective, Objective, Medical Management, Analytic scale.62 
3.2.2 SNP analysis: genome wide association studies 
An alternative to candidate gene studies is genome-wide association analysis (GWAS). Contrary to the 
targeted candidate gene approach, GWAS casts a wide net to sieve out moderate levels of signal in noisy 
genomic data.52 The threshold for statistical significance is more stringent to account for the increased 
number of independent hypotheses performed in GWAS (one per SNP) and thus larger sample sizes are 
typically required to find statistically-informative associations. Recent GWAS , including meta-analysis, by 
RgC members have identified several novel SNPs associated with genes which were not previously linked 
to radiotherapy toxicity.63 These genes include TANC1, which encodes a repair protein for muscle 
damage,64 and KDM3B and DNAH5, which encode proteins expressed in urinary tract and were associated 
with increased urinary frequency and decreased urinary stream, respectively.65 
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3.2.3 Beyond SNPs 
Copy number variation (CNV) or gene dosage is another genetic alteration that is estimated to account 
for 4.8-9.5% of the genome.66 A CNV exists when a DNA segment 1 kb to several Mb in length is either 
deleted or duplicated compared to a reference genome.67 The objective of CNV analysis is to determine 
how many copies of a gene regions deviates from two, representing a reference gene with one copy from 
each homologous chromosome. CNVs have been implicated in several diseases, but their role in 
radiotherapy toxicity is nascent. In a proof-of-concept study, Coates et al. incorporated XRCC1 SNP and 
CNV features into classic models to improve performance.68 
In a very large pre-clinical study, Yard et al. illustrated the rich space of CNVs, gene mutations, and 
gene/gene set expressions by exposing over 500 cell lines to radiation.69 Radiosensitivity was enriched in 
gene sets associated with DNA damage response, cell cycle, chromatin organization, and RNA metabolism. 
In contrast, radioresistance was associated with cellular signaling, lipid metabolism and transport, stem-
cell fate, cellular stress, and inflammation. 
4 Tumor radiosensitivity 
Tumor radiogenomics has focused on finding gene expression assays to determine radiosensitivity.3,70 The 
general goal of these assays or models is to predict whether an individual benefit would be more served 
by radiotherapy compared to an alternative treatment.  
Tumor genomics should be distinguished from germline genomics as the former is usually using genetic 
information from tumor tissue whereas the latter is using DNA taken from normal tissues, typically blood 
or saliva (Table 1). There are exceptions as described below with MRE11A and later with multi-omics 
models by the El Naqa group.71 
Table 1: Examples of tumor gene expression assays/models and consortia for germline polygenetic assays 
 
 
4.1 Gene expression to predict radiotherapy benefit 
Pre-treatment bladder cancer expression of DSB repair gene MRE11 was found to be predictive of survival 
following radical radiotherapy but not cystectomy by the Kiltie group,72 a result that was independently 
verified by Laurberg et al.73 Interestingly, the SNP rs1805363 in MRE11A was also found predictive of 
survival in a gene-dosage effect in patients with bladder cancer treated by radical radiotherapy but not by 
Poly-gene expression assays
(tumor behavior)
Polygenic germline genomics
(normal tissue risk)
General oncology Cancer development risk
Breast: Oncotype DX®, MammaPrint® Consortiums for prostate cancer (PRACTICAL),
Prostate: Decipher®, Prolaris® breast cancer (BCAC), ovarian cancer (OCAC)
Radiation oncology Radiotherapy toxicity risk
Prostate: post-operative radiation therapy 
outcomes score (PORTOS)
Radiogenomics Consortium
Various tumors: genome adjusted 
radiation dose (GARD)
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cystectomy.74 New work by the Kiltie group aimed to standardize and develop a clinical assay for MRE11 
immunohistochemistry assay across several centers in the United Kingdom using transurethral resection 
of bladder (TURBT) samples from prior bladder-preservation trials.75 However, they were unable to 
replicate prior results, which was attributed to problems in automatic staining and poor scoring 
reproducibility among histopathologists. 
The Post-Operative Radiation Therapy Outcomes Score (PORTOS) is a 24-gene predictive assay that was 
retrospectively trained on post-prostatectomy prostate cancer samples from patients, some of who 
received postoperative radiotherapy.76 The authors used gene ontology to find gene sets enriched for 
DNA damage and radiation response. Using a final pool of 1800 genes, a univariable screen was used for 
ranking, followed by ridge regression-penalized Cox modeling of distant metastasis free survival to 
determine which patients would benefit from post-operative radiation therapy.  
The radiosensitivity index (RSI) was developed at Moffitt Cancer Center to predict radiosensitivity in 
several tumor cell lines.77 The RSI signature is a linear regression of the expression of 10 genes (AR, cJun, 
STAT1, PKC, RelA, cABL, SUOMO1, CDK1, HDAC1, IRF1) with the outcome variable being survival fraction 
at 2 Gy (SF2). The selected genes are implicated in pathways involved in DNA damage response, histone 
deacetylation, cell cycle, apoptosis and proliferation. In patients, RSI predicted for improved progression 
free survival in cohorts treated with adjuvant radiation but not in unirradiated controls in several tissue 
types, including breast cancer,78 lung cancer,79 and prostate cancer.80 More recently, Scott et al. combined 
RSI with  the linear quadratic model to create the Genome Adjusted Radiation Dose (GARD).81 The goal of 
GARD is to unify a model of both radiobiologic and genomic variables to predict for radiation response, 
and provide a quantitative link from genomics to clinical dosing. There is discussion regarding whether 
GARD is truly prognostic or predictive as the radiation dosage component is a modifiable input.33,34 
Another class of molecules that has gained interest are micro RNAs (miRNA) which are short, stable 
sequences of RNA which act to inhibit expression of messenger RNA (mRNA).82 Pretreatment serum levels 
have been found to correlate with radiotherapy response cancers of the lung83 and head and neck.84,85 
miRNA upregulation can occur just hours after ionizing radiation.86 
4.2 Prognostic or predictive radiation signatures 
As there was no alternative treatment that patients could have received instead of radiation in the 
populations used to train RSI/GARD or PORTOS, it remains unclear whether these tests are acting as 
specific biomarkers of radiotherapy benefit or whether they serve as general markers for treatment 
sensitivity. In other words, perhaps a similar benefit or even increased benefit would be seen with 
systemic therapy or other therapy. Without comparison to alternative therapies, there will remain a 
question of whether radiation is the correct choice in a space increasingly crowded with targeted 
therapies, immunotherapy, and salvage surgery. As the MRE11 studies did train models on patients who 
received either radical radiotherapy or cystectomy, it would be correct to say that MRE11 expression does 
predict for radiotherapy benefit vs. surgery. However, it should also be cautioned that this predictive 
ability could be due to confounding variables or other latent factors, particularly as initial clinical validation 
was unsuccessful (discussed above75). Thus, while MRE11, PORTOS, and RSI/GARD remain to be 
prospectively or randomly validated, they are a promising harbinger of future radiogenomics assays to 
determine benefit from radiation. 
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Tumor sensitivity assays remain of active interest. In the newly published Children’s Oncology Group ACNS 
0121 phase 2 trial, improved event free survival (EFS) was seen in pediatric infratentorial ependymomas 
receiving chemoradiation who had focal copy number gain on chromosome 1q compared to those without 
1q gain (83% vs. 47%, p=.0013).87 As there was no cohort with focal 1q copy number gain that did not 
receive chemoradiation therapy, we do not know whether this mutation is predictive of chemoradiation 
response or general prognostic indicator. 
5  Radiogenomic modeling: mechanistic, data-driven 
and machine learning methods 
The following section highlights methods and examples of different frameworks for radiogenomics 
modeling that will be discussed in this section (Figure 1). We first discuss augmentation strategies for 
“classical” (dose- and volume-based) outcomes models to allow the integration clinical and biological data 
(“augmentation”). We then discuss data-driven modification of these models as well as data-driven 
models that use machine learning.  
 
Figure 1: Schematic comparing modeling frameworks for mechanistic vs. data-driven models with select examples 
discussed in this review. GARD: Genome-Adjusted Radiation Dose81; PORTOS: Post-Operative Radiation Therapy 
Outcomes Score76; PRFR: preconditioned random forest regression88 
5.1 Classical models 
Normal tissue complication probability (NTCP) models attempt to predict the risk of specific normal tissue 
side effects induced by radiotherapy. Examples include radiation fibrosis in the lungs or erectile 
dysfunction after prostate radiotherapy. These toxicities reflect both cell death as well as non-cell death 
related tissue injury, including inflammatory reactions and late effects. Until recently, such predictive 
models have relied almost exclusively on semi-mechanistic interpretations of dose and volume data to 
understand the effects of ionizing radiation.89,90 In this paper, we refer to “mechanistic” models of NTCP 
to describe these simplified, semi-mechanistic models, such as the Lyman-Kutcher-Burman model.91 It is 
now apparent that more complex genetic and biological factors can play a significant role in determining 
and modulating tissue radiosensitivity, often in non-linear ways.92 Pragmatically, NTCP models based on 
dosimetry-alone risk lacking robustness across cohorts potentially limiting their usefulness clinically. 
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Biological risk factors integrated into classical outcome models generate “augmented” (or “mixed”) 
models. This approach can also be extended to clinical risk factors as well. The impact of integrating a 
validated biological risk factor is visualized in Figure 2a in the change of NTCP curve slope and absolute 
value according to different generalized equivalent uniform doses (gEUDs). A corresponding shift is 
showcased in Figure 2b for the same theoretical, dichotomous biological risk factor (present or absent) 
but is plotted with separate dose and volume components in three-dimensional space. These figures use 
mock input data but show changes similar in magnitude to those in literature.92–94  
 
Figure 2: Theoretical impact of integrating validated biological risk factors on predicted NTCP curves (a) and surfaces 
(b). Solid curves indicate theoretical NTCP values derived from dose and volume metric-based models. Dashed curves 
reflect a dosimetric model that has been augmented with a dichotomous biological risk factor (radiogenomic). In (a), 
NTCP values were generated using the Lyman-Kutcher-Burman (LKB) model with mock generalized equivalent 
uniform dose (gEUD) values yielding NTCP values with or without a risk factor (as indicated).  Surfaces in (b) were 
similarly generated with mock values for dose and volume parameters making separate gEUD-based planes. 
In order to generate NTCP curves, there exists two overarching modeling approaches: data-driven and 
mechanistic. Data-driven approaches use statistical techniques to identify trends and correlations in data 
while mechanistic approaches95,96 (also known as analytical techniques) rely on certain simplifying 
assumptions to reflect experimental observations. The methodology for augmenting a model can vary 
widely depending on the chosen strategy and is therefore equally important to consider. In the below 
sections, we discuss types of biological factors used in augmenting models and associated strategies with 
relevant examples. 
5.1.1 Integration of biological variables 
SNPs reflect single changes in nucleotide sequences and their incorporation into NTCP models has become 
more common recently although most findings remain to be validated on large cohorts. If found in coding 
regions, SNPs may induce conformation or enzymatic changes to transcripts or proteins. For NTCP 
modeling, these changes could affect DNA repair capabilities, signal transduction, or other elements of 
the DNA damage response (DDR) cascade.97  In the case of SNPs that do not reside in protein coding 
regions, mechanistic influence on outcomes is less clear but could theoretically relate to transcript 
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splicing, binding, or degradation.98 As discussed above, SNPs of interest were historically sought using 
candidate gene approaches and most reports related to DDR pathways.2,99 
Previously, our group demonstrated that more substantial changes to the genome could be useful for 
outcome modelling in addition to SNPs for predicting late effects in prostate cancer radiotherapy.68 
Resulting radiogenomic models incorporating SNPs, CNVs, and dosimetry led to increased cross-validated 
predictive power when compared to dosimetric- or genetic-only models. The CNV of DNA repair gene 
XRCC1 was found to be particularly useful for predicting severe rectal bleeding (Grade ≥3) or erectile 
dysfunction (Grade ≥1) when combined with dosimetry. Though improvement in cross-validated 
prediction performance was found for both data-driven and mechanistic modeling strategies, 
performance was higher in the case of data-driven models compared to mechanistic ones. Given the 
limited sample size (n=54), the worse performance of the mechanistic model may reflect incorrect 
assumptions introducing a bias, which can be compensated for in the data-driven model. Thus, the relative 
difference in performance observed in the study may be dependent on the modeling frameworks 
employed. 
In the case of augmenting existing mechanistic models, it is important to consider how variables such as 
the binary presence of genetic variants are incorporated mathematically to avoid nullifying model output 
in the absence of the risk factor; this principle applies similarly to clinical risk factors. The use of dose-
modifying factors (DMFs) maps existing parameters into an exponential function to avoid misbehaved 
outputs (e.g., when it goes to zero or ∞).68,93,100 In contrast, data-driven approaches are readily able to 
integrate dichotomous and continuous data. 
5.1.2 Modulating dose in classical models 
The most frequently employed dosimetry-based NTCP model in use is the Lyman-Kutcher-Burman (LKB) 
model (Eq. 1a-c):101 
      (1a) 
where Φ(𝑡) is the normal cumulative distribution function: 
     (1b) 
consisting of: 
   and        (1c) 
where TD50(1) is the dose at which NTCP is 50% for an endpoint, m the slope, and TD50(V) is the partial 
volume tolerance dose, and n is the tissue-specific volume exponent.  
Formulaically, the LKB model is based on a sigmoidal error function and stratifies patient risk according to 
how much larger or smaller the gEUD is relative to the TD50. The gEUD is a three-dimensional DVH 
reduction technique and so spatial information on dose distribution is not fully retained; the 
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dimensionality of the problem is significantly reduced by sacrificing details of the spatial dose distribution 
(see Section 5.4.3 for relevant discussion on feature transformation). Consequently, the LKB model and 
its variants (described below) best describe toxicities related to uniform doses of all or part of an organ. 
Depending on whether the canonical LKB model is employed and the treatment conditions or endpoint 
considered, the LKB model is sometimes referred to as semi-mechanistic due its relatively simplistic 
formulation derived from the normal cumulative distribution function. The modified LKB model102 (Eq. 2a-
b) allows for the inclusion of biological risk factors whether they are dichotomous or not: 
 
 
NTCP = 1
2p
e
-u2
2
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t
ò du
t =
Deff - TD50 × DMF1 × DMF2 × ... × DMFk
m ×TD50 × DMF1 × DMF2 × ... × DMFk
  (2a) 
where each DMF is defined by: 
 𝐷𝑀𝐹௞ = 𝑒ఋೖ∙ோೖ (2b) 
wherein δk is the risk-factor weight for risk-factor k, and Rk indicates the presence (Rk=1) or absence 
(Rk=0) of the risk-factor for a given patient. 
The GARD/RSI model discussed above is a practical example of augmenting the linear-quadratic model of 
cell kill by adding gene-expression derived parameters to create a patient-specific radiosensitivity assay.81 
5.2 Data-driven methods: statistical models 
Data-driven models (also known as phenomenological models) are built on statistical techniques that are 
empirical and frequentist.11 Classical models employ a more rigid mathematical basis (typically around a 
mechanistic basis) around which goodness-of-fit is sought, whereas data-driven statistical models have 
less restrictions and assumptions. The robustness of data-driven models relates to how often observations 
(data or variables) can be related to an outcome according to certain relationships (equations). As such, 
data-driven NTCP models may be able to identify models that perform better than mechanistic 
counterparts, given sufficient data, or that depart significantly from standard therapeutic strategies, such 
as charged particle therapy.103 
Data-driven NTCP models are most often regression-based and sigmoidal in shape. The reasons for this 
are that regression-based techniques can be trained in a practical amount of time such that prospective 
clinical use is feasible. Secondly, the experimentally observed sigmoidal relationship seen with ionizing 
radiation and cell death can be reflected by regression-based models by using sigmoidal link functions. 
Let 𝜋(𝑥௜) be the desired probability considered as a function of the input variable(s) 𝑥௜. Then, the most 
commonly used link functions are the inverse of the normal cumulative distribution function, or probit 
(Eq. 3), and the logit function (Eq. 4): 
Φିଵ൫𝜋(𝑥௜)൯ = 𝑔(𝑥௜)     (3) 
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log ቀ గ(௫೔)
ଵିగ(௫೔)
ቁ = 𝑔(𝑥௜)     (4) 
where 𝑔(𝑥௜) is the generalized linear formulation of the input variable(s), 𝑥௜: 
    (5) 
having β as coefficients that are identified via optimization, e.g. maximum likelihood estimation. 
Increased generalizability for data-driven models may also originate from frameworks having to first 
choose whether to include a variable or not (model order estimation) prior to fitting coefficients.104 In 
contrast, mechanistic modelling approaches require that some or all parameters be included and 
therefore only be modulated, which may limit generalizability due to forcing features into the model. 
The PORTOS assay discussed above is a practical example of augmenting Cox regression survival analysis 
with gene-expression derived tumor radiosensitivity.76 
5.3 Data-driven methods: interpretable machine learning 
Machine learning (ML) evolved from a recent cross-pollination between computer science and statistics. 
As owed to their computer science origin, most ML models are “data-driven” techniques as they do not 
attempt to model simplified mechanisms105 (as is done in the mechanistic/analytical approach) and 
instead statistically translate inputs into probabilities that appear sigmoidal, though the specific link 
function is a user-set hyperparameter. Due to the focus on using data to make predictions but not in 
inferring the processes behind data generation, many ML methods are rightly described as having poor 
interpretability. Improving interpretability is of particular value in clinical decision support models106–109 
and is a high priority research area in ML, being the subject of a Neural Information Processing Systems 
symposium in 2017.110 
Some data-driven models in ML attempt to provide a more interpretable context. The progression of 
Bayesian network approaches by the El Naqa group provides a case study of more interpretable, multi-
objective modeling in radiogenomics, as described below. 
5.3.1 Bayesian networks 
Bayesian networks (BN) are directed graphical models with probability distributions.111 The graph is 
represented by nodes (vertices) connected by links (edges) that represent probabilistic relationships 
between the variables. The graph then captures joint distributions between subsets of the variables. In 
fact, relationship between nodes in a BN can be deconstructed into a series of joint probabilities. BNs are 
subject to an important restriction of being acyclic: there must not be a closed path from a node to 
another node along links following the direction of the arrows. Despite their name, they can be used for 
either frequentist or Bayesian inference.112  
Like decision trees, BNs are graph-based methods that are reasonably interpretable and can incorporate 
variables from different domains without extensive pre-processing. A disadvantage is that continuous 
variables are typically discretized as many BN learning algorithms cannot efficiently handle continuous 
variables and common software packages do not support continuous variables.113 In radiogenomics, BN 
 
g xi( ) = bo + b j Xij ,i =1,...,n, j =1,...,s
j=1
s
å
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nodes represent genes or proteins while the links between them represent probabilistic similarities or 
interactions.70 Due to these advantages, BNs have been used to incorporate both clinical and genomic 
variables to predict local control and/or toxicity.  
5.3.2 Single objective prediction: local control or toxicity 
Oh et al. used BN on two separate patient cohorts of locally-advanced non-small cell lung cancer (NSCLC) 
to predict local control (LC).71 The first cohort of 56 patients included clinical and dosimetric data. The 
second cohort of 18 patients also had serum markers drawn pre- and during-treatment: transforming 
growth factor β, interleukin 6, angiotensin converting enzyme, and osteopontin. Despite the small 
numbers, better performance was noted when clinical, dosimetric, and molecular data were all used. 
This BN framework was also applied to 54 locally advanced NSCLC patients to predict Common 
Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade 2+ radiation pneumonitis (RP2). Initially, a 
limited set of pre- and during-treatment molecular biomarkers was used along with clinical/dosimetric 
features (i.e., lung V20)114 but this was subsequently expanded to a heterogeneous set of 200 features, 
which included SNPs, cytokines and micro RNA (miRNA) biomarkers.115 Feature selection was performed 
using a stepwise wrapper method116 to find conditionally independent subsets (Markov blankets117).  
Predictive performance for these studies reached area under the receiver operating curve (AUROC) >0.80. 
5.3.3 Multi-objective prediction: local control and toxicity 
Prior radiogenomics studies have generally focused separately on either tumor control or toxicity. More 
recently, Luo et al. demonstrated a multi-objective approach using BN to simultaneously model LC and 
RP2 in a cohort of 118 NSCLC patients treated with radiotherapy.118 A total of 297 clinical, dosimetric, 
radiomic, and genomic features were initially considered. The genomic features were pre-selected from 
literature review and included micro RNA (miRNA), SNPs, and cytokine levels in serum. The cytokine and 
the metabolic radiomic features had values both pre- and during-treatment. By first training individual 
BNs for LC and RP2, the authors were able consider a smaller feature set of about 50 (i.e., only features 
important for either LC or RP2) to optimize a unified multi-objective BN that simultaneously modeled LC 
and RP2. This process was repeated using pre-treatment or during-treatment variables. While the 
validation set was heavily skewed with only 3/50 patients having RP2, this work does provide a conceptual 
framework that accounts for both LC and toxicity. 
5.3.4 Challenges of modeling therapeutic ratio 
The therapeutic ratio (therapeutic index) refers to the ratio of tumor response for a fixed level of normal 
tissue damage.119 Like many tradeoffs in statistics and ML—bias/variance, sensitivity/specificity—the 
multi-objective tradeoff between tumor control and toxicity in modern treatment planning follows5 the 
principles of Pareto optimality or efficiency where one outcome cannot be improved without worsening 
another.120  
While the work by Luo et al. demonstrates the feasibility of a multi-objective ML model that optimizes a 
joint AUROC, it does not allow one to give relative weight to LC vs. toxicity. There are several complicated 
issues to consider. First, LC and toxicity are not independent events as local recurrence in lung cancer after 
first-line therapy generally leads to additional salvage treatments, which could include additional 
radiation, surgery and/or systemic therapy. The toxicity profile is now magnified with no guarantee of a 
linear increase in toxicity. Secondly, RP2 may be an overly conservative endpoint as CTCAE v3.0 Grade 2 
pneumonitis is defined as “symptomatic, not interfering with ADL.” This issue relates to the differing 
weights that patients and physicians place on LC and toxicity. Patients may value LC more than toxicity 
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due to fear of recurrence121,122 whereas physicians may weigh toxicity more than LC.123 Whereas a tumor 
recurrence may be attributed to aggressive biology, physicians can be more certain of therapy-induced 
toxicity, which can induce recall bias of patients who had severe toxicity. Lastly, it can be very difficult to 
assess adverse events. Clinicians tend to underreport subjective treatment toxicities compared to 
patients, which is the impetus behind patient-reported outcomes.124,125 In the setting of a multi-objective 
model, being able to precisely define toxicity becomes of upmost importance due to the direct 
relationship with tumor control. Wider adoption of patient-reported outcomes could partially alleviate 
this issue. The addition of transcriptomic or proteomic information from the tumor tissue itself (instead 
of circulating cytokines) would also likely improve the assay. 
In the future, we will likely see tumor expression panels such as PORTOS and GARD/RSI combined with 
germline toxicity panels to determine multi-objective optimization for therapy aggressiveness. Such 
radiogenomic approaches that can increase the therapeutic ratio are sorely needed. 
5.4 Data-driven methods: high dimensionality machine 
learning 
While many of the classic ideas and methods in machine learning (ML) were developed several decades 
ago, the exponential increase in computing power126 has recently allowed high-dimensional ML models 
to be trained in a reasonable timeframe. However, there is often interest in only using certain features of 
the dataset. Libbrecht and Noble describe three reasons for feature selection in machine learning for 
genomics: (1) identify a subset of features that retains good predictive performance, (2) understand 
biology through the principle of parsimony, and (3) improve performance by removing variables that are 
contributing noise.7 The authors note that it is usually very difficult to perform all three simultaneously. 
Feature selection in genomics is difficult not only due to the large number of features (i.e. SNPs, CNVs, 
etc) involved, but also due to the complex biology represented. This complexity can result in low “signal 
to noise” that can make predictive models difficult to train. 
High-dimensional feature selection is an active area of research in genomics.127 More generally, it has long 
been an active area of research among statisticians, particularly so for regression problems. Arguably, 
these efforts began with the introduction of forward variable selection,128 where it has since been 
established that forward and related methods of stepwise regression (i.e., wrapper methods) are fraught 
with numerous inferential challenges.129 Modern approaches to variable (i.e., feature) selection in 
regression and classification vary in scope and complexity, including approaches that utilize univariate 
screening (or filtering) procedures,130,131 penalized regression or classification methods (e.g., lasso,132 
elastic net133), and combinations thereof.134 The statistical properties of these newer methods are 
necessarily studied under certain sparsity assumptions, where (i) the number of available predictor 
variables (e.g., SNPs) can vastly outstrip the number of independent replicates (e.g., subjects) but (ii) the 
number of important variables is much smaller. Despite the many important advances in both estimation 
and inference in the presence of variable selection that has been made since the introduction of the lasso, 
numerous unresolved challenges remain and research into these problems continues. 
Consequently, feature selection in genomics relies on custom combinations of filters, wrappers, 
embedded methods, and dimensionality-reduction. These methods have their own advantages and 
disadvantages that will be further discussed (Table 2). The optimal process of sequencing and combining 
feature selection methods with domain expertise has not been well established and is more of an “art.” 
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Table 2: Feature selection methods discussed in Section 5.4 with examples, advantages and disadvantages. PCA: 
principal component analysis. 
 
 
5.4.1 Filtering: pre-processing independent of model 
In filtering, the features are pre-selected using a type of screen that is independent of the model choice. 
Filtering increases robustness to overfitting by reducing variance at the expense of increasing bias:135 
there is an assumption that the remaining variables are sufficient for explaining a model’s behavior. There 
is usually also an assumption that correlation between variables can be ignored. Prior to formal analysis, 
GWAS studies use quality control filters which can consist of testing for SNPs out of Hardy-Weinberg 
equilibrium, with a high missing proportion, or with a low minor allele frequency.136,137 
In high dimensional problems scenarios like GWAS, millions of hypothesis tests are performed. By random 
chance, there is a near-guarantee of finding effects that are falsely labeled as statistically significant if 
there is no correction to the pre-specified significance level α.138 Several techniques are commonly used 
in GWAS to correct for the probability of Type I errors, which is the risk of rejecting a true null 
hypothesis.139 A Type I error can also be described as a false positive. Two important methods for 
controlling Type I error include the familywise error rate (probability of at least one Type I error) and the 
false discovery rate (the expected proportion of false discoveries).140 One common familywise error rate 
method is Bonferroni correction, which involves dividing the α of a single hypothesis test (i.e., the 
threshold for obtaining a surprising result assuming no difference; often set at α = 0.05) by the number of 
independent tests performed. For example, in a GWAS with approximately 1 million independent SNPs 
being evaluated individually, the corrected α would be set to 0.05 ÷ 106 = 5×10-8. Use of Bonferroni 
correction to account for multiple hypothesis testing has become standard practice in genetic association 
studies, including those focused on radiotherapy outcomes.65,141 
The main weakness of univariable filtering is that it does not account for interactions between features 
and thus is unable to explain non-linear behavior between features, such as epistatic interactions.142 
Epistatic interactions are difficult to find and interpret in genomics, as a statistical interaction does not 
necessarily imply a biological interacton.127,143,144 In the most extreme scenario, a variable may have no 
marginal effect (i.e., no independent effect or main effect) and only be detected through an interaction 
when combined with another variable. To address this weakness in univariable filtering, multivariable 
methods such as the ReliefF family take an ensemble approach to rank variables.145–147 Other options 
include incorporating feature selection into model building, as discussed below. 
Feature selection method Advantage Disadvantage
Filter
(t-test, chi-squared)
fast; statistical inference ignores interactions
Wrapper 
(stepwise selection)
multivariable interactions;
widely implementable
slow;
inferential challenges
Embedded 
(lasso, elastic net)
balances complexity
with performance
model-specific;
assumes sparsity; 
inferential challenges
Transformation 
(PCA, manifold learning)
partially preserves information;
uses unlabeled data
unclear interpretability
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5.4.2 Wrapper and embedded feature selection 
Wrapper methods and embedded feature selection methods both incorporate feature selection into the 
model building. Wrappers are model-agnostic methods that select among feature subsets by 
incorporating (“wrapping”) the model being assessed into the feature selection process.148 Examples 
include stepwise forward selection, backward elimination, and genetic algorithms.135  
Embedded methods are model-specific and typically multi-objective in that they balance predictive 
performance with model complexity. An example is regularization, which adds a penalty parameter to a 
method’s objective function to control for complexity. While superficially similar to information theory 
approaches in that both control for complexity, regularization is part of the internal model optimization 
process whereas information criterion approaches are used for model selection.149 Genomics uses 
regularization extensively to decrease the polygenic complexity and decrease variance.150 Common 
usages include linear regression regularization aimed to prevent the beta coefficients from growing too 
large (ridge regression151), to shrink the number of non-zero beta coefficients (lasso regression132), or both 
(elastic networks133).152,153 A related two-step method called stability selection was developed for very 
high dimensional variable selection.154 A subsampling step is first used to determine the amount of 
regularization and is then followed by a lasso step. 
Due to their ability to consider epistasis during model fitting, regularized ML methods have been 
combined with filters using two-stage approaches. Unlike traditional two-stage GWAS,155–157 these 
combined methods add an ML step to hypothesis testing using either data split or resampling. This 
combination attempts to balance sensitivity with false discovery by using screening tests to detect low 
signal, linear interactions and ML to train cross-validated prediction models of non-linear interactions.143 
In principle, this staged design can also take advantage of the plateau in statistical power curve at high 
sample sizes to contribute cases to an ML method where learning error often obeys an inverse polynomial 
function (Figure 3).158–160 
 
Figure 3: Sample plots of statistical power and learning curve error. Statistical power graph derived using Genomic 
Association Studies power calculator.161 Learning curve assuming an inverse power law common to multiple machine 
learning methods.158–160 Reproduced from Kang et al.9 with permission by publisher Frontiers 
(https://www.frontiersin.org) 
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“Screen and clean” is an example of a two-stage model that performs lasso regression (“screen”) on split 
data using a dictionary of pairwise interaction terms that is then followed by hypothesis testing (“clean”) 
on remaining data.134 This method has been applied to model SNP interaction and main effects.162 A similar 
method reverses the order of lasso and hypothesis testing.163 
The COMBI method for GWAS combines a linear support vector machine (with SNPs weighted using a 
moving average filter) and hypothesis testing using resampling to correct for familywise error rate.164 
Using training data from a 2007 Wellcome Trust Case Control Consortium GWAS study, Mieth et al. report 
higher power and precision to detect SNPs replicated in independent GWASes from 2008-2015 as 
compared to traditional and “screen and clean” based methods. COMBI also had fewer false discoveries, 
with 80% of discovered SNPs being validated in prior studies. 
Similar two-stage approaches have been used with random forest (RF) and chi-squared test to select for 
SNPs.165,166 RF and similar ensemble-tree model have been very popular due having built-in feature 
importance measures.167 In simulations of GWAS, variable importance measures using RF demonstrated 
superior power to discover associations with disease compared to linear regression and dimensionality 
reduction methods.168 While RF can provide measures of variable importance, there are limitations to 
inference and interpretability for variables. Generally, RFs and related approaches do not do variable 
selection—meaning, (a) there is no dimension reduction and (b) it is impossible to directly carry out tests 
of significance (without methods like resampling of synthetic data168), especially when the number of 
predictors approaches or exceeds the number of samples. Additionally—and perhaps as a result—there 
is disagreement about RF’s ability to detect pure epistatic interactions compared to marginal effects.169,170 
5.4.3 Unsupervised learning: feature transformation/construction 
Feature transformations are popular methods for both decreasing the number of features and 
reconstructing the data to improve predictive performance. These methods compress the original 
features into fewer new ones that aim to preserve most of the original information. Unsupervised learning 
methods are used as they do not require labeled outputs and instead look for interesting substructures 
or relationships. These relationships can be between inputs or between inputs and outputs. 
Clustering is a general class of methods that groups observed features into fewer features called centroids 
and assigns every data point to one of these centroids. The most popular clustering method for feature 
transformation is k-means clustering. Another popular method is hierarchical clustering, which aims to 
preserve the bottom-up tiered processes seen in biology.  
Another popular transformation method is principal component analysis (PCA), which is motivated by 
eigenvector analysis. PCA finds the directions of highest variance in the dataset that are statistically 
uncorrelated (i.e., all orthogonal to each other). The direction of largest variance is the first principal 
component (PC), the second highest variance is the second PC, and so on. While PCA is often used for 
feature selection, it is also used in GWAS to control for potential confounding by ancestry or batch 
effects.171,172 
Methods like k-means and PCA can be effective for finding basic substructures (well-separated, globular 
shapes) but do not work well for more irregular shapes. A class of methods called manifold learning 
algorithms is aimed to find low dimensional structure in high dimensional data. Multidimensional scaling 
(MDS) is one such method that aims to preserve information about the proximity of data points to each 
other. In genomics, MDS is used as an alternative to PCA.150 A newer method called t-SNE finds a two-
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dimensional representation of data such that the distances between points in the 2D scatterplot match 
the distances between the same points in the original high dimensional dataset.173–175 
Kernel-based methods such as support vector machines can transform features in higher dimensions 
where analysis may be easier.176 Neural networks are another popular ML method that specializes in 
constructing features within the hidden layers after being initialized with observed features.  
5.4.4 Multi-step feature selection in radiogenomics 
Oh et al. apply several feature selection methods to GWAS data to create preconditioned random forest 
regression (PRFR) for prediction of rectal bleeding and erectile dysfunction after prostate radiotherapy.88 
The SNPs are initially pre-filtered for quality control, resulting in approximately 600,000 SNPSs in 368 
patients. Stepwise forward selection of the SNPs into PCA was performed through inputting the first 1-2 
principal components into logistic regression to predict binary toxicity outputs. By mapping transformed 
SNPs in logistic regression to predict binary toxicities, continuous “pre-conditioned outcomes” are created 
which are highly correlated with both the binary toxicities and the inputs.177 The original SNPs were input 
into random forest regression to predict the preconditioned outcomes and validated on holdouts of the 
original samples. SNP importance rank was assessed using out-of-bag performance and inclusion in known 
biological pathways. Using this method, several genes implicated in ion transport and vascular regulation 
were found to be important for rectal bleeding and erectile dysfunction, respectively. This process was 
also applied to predict genitourinary toxicity and find associated gene ontology terms.178  
Table 3 summarizes PRFR and select radiogenomics models previously discussed. 
Table 3: Summary of select radiogenomic models that were discussed in this review. SNP: single nucleotide 
polymorphism; UM: University of Michigan; LC: local control; RP2: Grade 2+ radiation pneumonitis; PORTOS: Post-
Operative Radiation Therapy Outcomes Score76; DMFS: distant metastasis free survival; RSI/GARD: Radiosensitivity 
Index/Genome-Adjusted Radiation Dose81; PRFR: Preconditioned Random Forest Regression88; PCA: principal 
component analysis 
 
6 Conclusion 
As polygenetic assays to guide targeted systemic therapy becomes more established, the next logical step 
is to use genomics of tumor and normal tissues to better counsel patients and, ultimately, improve the 
therapeutic ratio in radiation oncology. As discussed, several tumor radiosensitivity panels have been 
developed and continue to undergo validation, including GARD, PORTOS and the Bayesian network 
approach for multi-omics. The PORTOS assay for post-prostatectomy radiation is now listed in the NCCN 
guidelines under the GenomeDX Decipher® platform.25 PRFR and other radiotoxicity models based on SNPs 
identified via GWAS are also undergoing active development. The high-dimensionality and lower signal-
to-noise in GWAS has been challenging, but efforts through the Radiogenomics Consortium to pool 
cohorts and apply new methodologies aim to address these issues. 
Radiogenomic model Application Model type Feature selection method
Chi-square genome-wide significance of SNPs statistical inference unvariate filter
UM Bayesian network balance LC & RP2 after lung radiation interpretable graph stepwise wrapper
PORTOS DMFS after prostatic-bed radiation augmented statistical candidate gene & filtering
RSI/GARD various tumors' survival in vitro/in vivo augmented mechanistic uni-/multi-variable regression
PRFR toxicity after prostate radiation transformed random forest filter, stepwise PCA
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New cooperative group phase III trials led by radiation oncology investigators have begun to incorporate 
genomic considerations in primary and secondary endpoints.179–181 The future of genomics in radiation 
oncology is promising but will require multidisciplinary collaboration between physicians, radiobiologists, 
and medical physicists/informaticians in cooperative group settings to best utilize the spectrum of clinical 
applicability, biological considerations, and analytic principles. 
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